Regardless of the diabetes type, glucose control aims to prevent microvascular complications. Besides acute metabolic decompensation settings, appreciation of this control is mainly based on determining past and current HbA1c levels while documenting the occurrence of hypoglycemia episodes. Recently, the Social Security has made available to Type 1 diabetes patients the continuous measurement of interstitial glucose by means of subcutaneous sensors. On account of this therapeutic advance, we have now to consider new statistics and glycemic targets based on ambulatory glucose profiles generated in this way, including the concept of time spent within the target area.
Key Words
Glycemia; diabetes; HbA1c; interstitial glucose